No Data
No Data
CICC: Maintaining China Resources Healthcare's (01515) “Outperform the Industry” Rating Target Price of HK$5.6
The Zhitong Finance App learned that CICC released a research report stating that it maintained China Resources Healthcare's (01515) “outperforming the industry” rating and maintained 2024/2025 net profit of RMB551/715 billion, an increase of 113.8%/29.8% over the previous year, with a target price of HK$5.6. The company announced its 2023 results: revenue of RMB 10.108 billion, up 27.9% year on year; net profit to mother of RMB 258 million, a decrease of 3.1% year on year, in line with the forecast. CICC's main views are as follows: further expansion of the hospital network layout, hospital industry
China Resources Healthcare (01515.HK): Performance is in line with expectations, gross margin increased year-on-year
The 2023 results are in line with our expectations. The company announced the 2023 results: revenue of RMB 10.108 billion, up 27.9% year on year; net profit to mother of RMB 258 million, a decrease of 3.1% year on year, which is in line with me
China Resources Healthcare (01515.HK): Steady growth in hospital revenue and increasing profit contribution
Core view: The company disclosed its 23-year results announcement. The hospital business revenue grew steadily, and the adjusted division performance margin increased. Revenue for year 23 was 10.108 billion yuan, +79.8% year-on-year (if Liao Jian is not included in the same period in '22
CR MEDICAL To Go Ex-Dividend On June 7th, 2024 With 0.0661 HKD Dividend Per Share
March 20th - $CR MEDICAL(01515.HK)$ is trading ex-dividend on June 7th, 2024. Shareholders of record on June 11th, 2024 will receive 0.0661 HKD dividend per share on July 19th, 2024. The ex-divide
Hong Kong stock changes丨China Resources Medical rose more than 3%, revenue increased 27.9% year-on-year in 2023, and proposed a final interest rate of $0.06 per share
Gelonghui, March 20 | China Resources Healthcare (1515.HK) is now up 3.61% to HK$4.02, temporarily trading HK$14.86 million, with a current market value of HK$5.2 billion. China Resources Medical announced its annual results for the year ended December 31, 2023 yesterday evening. During the period, it achieved revenue of 10.108 billion yuan (RMB, same below), an increase of 27.9% over the previous year. Owners of the parent company should account for an annual profit of $258 million, and holders of common equity interests in the parent company should account for $0.20 per share (basic and diluted). It is recommended to distribute a final dividend of $0.06 per share. During the reporting period, the hospital business turnover was 94
Announcement Highlights: Xiaomi Q4's adjusted net profit increased 236.1% year on year; Xiaopeng Motor Q4's adjusted net loss decreased by 19.9% year on year
Li Ning's revenue in 2023 was 27.598 billion yuan, an increase of 7.0%; China Unicom's profit due to equity holders in 2023 was 18.7 billion yuan, an increase of 11.8% over the previous year.
No Data